Egg-independent Vaccine Strategies for Highly Pathogenic H5N1 Influenza Viruses

Overview

Journal Hum Vaccin

Specialty Allergy & Immunology

Date 2009 Oct 31

PMID 19875936

Citations 21

Authors

Aseem Pandey

Neetu Singh

Suryaprakash Sambhara

Suresh K Mittal

Affiliations

Soon will be listed here.

Abstract

The emergence of a highly pathogenic H5N1 influenza virus in Hong Kong in 1997 and the subsequent appearance of other H5N1 strains and their spread to several countries in southeast Asia, Africa, the Middle East and Europe has evoked fear of a global influenza pandemic. Vaccines offer the best hope to combat the threat of an influenza pandemic. However, the global demand for a pandemic vaccine cannot be fulfilled by the current egg-based vaccine manufacturing strategies, thus creating a need to explore alternative technologies for vaccine production and delivery. Several egg-independent vaccine approaches such as cell culture-derived whole virus or subvirion vaccines, recombinant protein-based vaccines, virus-like particle (VLP) vaccines, DNA vaccines and viral vector-based vaccines are currently being investigated and appear promising both in preclinical and clinical studies. The present review will highlight the various egg-independent alternative vaccine approaches for pandemic influenza.

Citing Articles

Post-marketing surveillance study on influenza vaccine in South Korea using a nationwide spontaneous reporting database with multiple data mining methods.

Lee H, Hong B, Kim S, Kim J, Choi N, Jung S Sci Rep. 2022; 12(1):20256.

PMID: 36424402 PMC: 9691710. DOI: 10.1038/s41598-022-21986-8.

Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.

McMillan C, Cheung S, Modhiran N, Barnes J, Amarilla A, Bielefeldt-Ohmann H NPJ Vaccines. 2021; 6(1):135.

PMID: 34750396 PMC: 8575991. DOI: 10.1038/s41541-021-00395-4.

Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.

Laurent A, Abdel-Sayed P, Hirt-Burri N, Scaletta C, Michetti M, de Buys Roessingh A Cells. 2021; 10(10).

PMID: 34685505 PMC: 8533713. DOI: 10.3390/cells10102526.

Development, Biological Characterization, and Immunological Evaluation of Virosome Vaccine against Newcastle Disease in Pakistan.

Rasool M, Mehmood A, Saqalein M, Nisar M, Almatroudi A, Khurshid M Biomed Res Int. 2021; 2021:8879277.

PMID: 33575353 PMC: 7864732. DOI: 10.1155/2021/8879277.

Plant-based vaccines and antibodies to combat COVID-19: current status and prospects.

Dhama K, Natesan S, Yatoo M, Patel S, Tiwari R, Saxena S Hum Vaccin Immunother. 2020; 16(12):2913-2920.

PMID: 33270484 PMC: 7754927. DOI: 10.1080/21645515.2020.1842034.

References

Luxembourg A, Evans C, Hannaman D . Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther. 2007; 7(11):1647-64. DOI: 10.1517/14712598.7.11.1647. View

Polo J, Gardner J, Ji Y, Belli B, Driver D, Sherrill S . Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel). 2001; 104:181-5. View

Ulmer J, Wahren B, Liu M . Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006; 12(5):216-22. DOI: 10.1016/j.molmed.2006.03.007. View

Lubeck M, Davis A, Chengalvala M, Natuk R, MORIN J, Mason B . Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A. 1989; 86(17):6763-7. PMC: 297926. DOI: 10.1073/pnas.86.17.6763. View

Bender B, Small Jr P . Influenza: pathogenesis and host defense. Semin Respir Infect. 1992; 7(1):38-45. View

Howard M, Kistner O, Barrett P . Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem. 2008; 389(5):569-77. DOI: 10.1515/bc.2008.060. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Geisbert T, Daddario-DiCaprio K, Geisbert J, Reed D, Feldmann F, Grolla A . Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26(52):6894-900. PMC: 3398796. DOI: 10.1016/j.vaccine.2008.09.082. View

Roberts A, Kretzschmar E, Perkins A, Forman J, Price R, Buonocore L . Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol. 1998; 72(6):4704-11. PMC: 109996. DOI: 10.1128/JVI.72.6.4704-4711.1998. View

10.

Vollmar J, Arndtz N, Eckl K, Thomsen T, Petzold B, Mateo L . Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2005; 24(12):2065-70. DOI: 10.1016/j.vaccine.2005.11.022. View

11.

ROBERTSON J, Nicolson C, Major D, ROBERTSON E, Wood J . The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol. 1993; 74 ( Pt 10):2047-51. DOI: 10.1099/0022-1317-74-10-2047. View

12.

Mayrhofer J, Coulibaly S, Hessel A, Holzer G, Schwendinger M, Bruhl P . Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol. 2009; 83(10):5192-203. PMC: 2682067. DOI: 10.1128/JVI.02081-08. View

13.

Audsley J, Tannock G . Cell-based influenza vaccines: progress to date. Drugs. 2008; 68(11):1483-91. DOI: 10.2165/00003495-200868110-00002. View

14.

Im E, Hanke T . MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines. 2004; 3(4 Suppl):S89-97. DOI: 10.1586/14760584.3.4.s89. View

15.

Huang Z, Elankumaran S, Panda A, Samal S . Recombinant Newcastle disease virus as a vaccine vector. Poult Sci. 2003; 82(6):899-906. DOI: 10.1093/ps/82.6.899. View

16.

Murray C, Lopez A, Chin B, Feehan D, Hill K . Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet. 2006; 368(9554):2211-8. DOI: 10.1016/S0140-6736(06)69895-4. View

17.

Ludwig C, Wagner R . Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007; 18(6):537-45. PMC: 7126091. DOI: 10.1016/j.copbio.2007.10.013. View

18.

Van Kampen K, Shi Z, Gao P, Zhang J, Foster K, Chen D . Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2004; 23(8):1029-36. DOI: 10.1016/j.vaccine.2004.07.043. View

19.

Ikonomou L, Schneider Y, Agathos S . Insect cell culture for industrial production of recombinant proteins. Appl Microbiol Biotechnol. 2003; 62(1):1-20. DOI: 10.1007/s00253-003-1223-9. View

20.

Kostense S, Koudstaal W, Sprangers M, Weverling G, Penders G, Helmus N . Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004; 18(8):1213-6. DOI: 10.1097/00002030-200405210-00019. View